SPRO
Spero Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.10
−1.35%Price chart
Oct 1Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30
Key dataOct 30, 2026
Open$1.12
From 52W high−63.26%
Volume112343.00
Market cap$63.77M
P/E (TTM)7.8x
P/S (TTM)1.5x
Div yield—
Key dataOct 30, 2026
Open
$1.12
From 52W high
−63.26%
Volume
112343.00
Market cap
$63.77M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
2.0x
P/E (TTM)
7.8x
RSI (14)
46.4
MomentumView details →
1D Return
−1.35%
YTD Return
−51.72%
SummaryUpdated Jun 1, 2026
Spero Therapeutics, Inc. (NASDAQ:SPRO) is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in Cambridge, Massachusetts. The company went public in November 2017 and focuses on developing novel treatments for multi-drug resistant bacterial infections and rare diseases. Spero has established strategic partnerships with major pharmaceutical companies including GlaxoSmithKline (GSK), Pfizer, and Everest Medicines to advance its pipeline of antibiotic candidates through clinical development and potential commercialization.
Similar companies
Latest newsMore news →